NCT06764355 - Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

ESCCTotal Neoadjuvant TreatmentPathological Complete Response

Interventions

DRUG

Tislelizumab

200 mg, 1h-IVF, Q3W on day 1 for 2 cycles

DRUG

Paclitaxel

Paclitaxel 175 mg/m2, 3h-IVF, Q3W on day 1 for 2 cycles

DRUG

Cisplatin

Cisplatin 75 mg/m2, 2h-IVF, Q3W on day 1 for 2 cycles

RADIATION

Chemoradiotherapy

"Chemoradiotherapy~* Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8,15, 22, and 29;~* Cisplatin 30 mg/m2,1h-IVF, on days 1, 8,15, 22, and 29;~* RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."